Mutations in EGFR, ERBB2, Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) (referred to hereinafter as ERBB family mutations) either occur alone or co-occur with PIK3CA mutations in 19% of HER2-positive breast cancers (n = 58) [21, 22]. This evidence concerns the gene ERBB2 and breast cancer.